ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!AGLE Company Profile and Key Details
Aeglea BioTherapeutics, Inc.
AGLE Stock Price Chart
Stock Price Today
Aeglea BioTherapeutics, Inc. (AGLE) stock surged +6.66%, trading at $12.01 on NASDAQ, up from the previous close of $11.26. The stock opened at $10.87, fluctuating between $10.69 and $12.34 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Company Information
| Employees | 69 |
| Beta | 2.57 |
| Sales or Revenue | $2.33M |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) stock price is $12.01 in the last trading session. During the trading session, AGLE stock reached the peak price of $12.34 while $10.69 was the lowest point it dropped to. The percentage change in AGLE stock occurred in the recent session was 6.66% while the dollar amount for the price change in AGLE stock was $0.75.
The NASDAQ listed AGLE is part of Biotechnology industry that operates in the broader Healthcare sector. Aeglea BioTherapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Linda Neuman M.D., MBA
Chief Medical Officer
Dr. Josie Gayton Ph.D.
Senior Vice President of Program Strategy, Operations & Chief of Staff
Dr. Kelly Boothe Ph.D.
Senior Director of Corporation Communications & Investor Relations
Joey Perrone
Vice President of Fin. & Investor Relations
Dr. Scott W. Rowlinson
Vice President of Research
Mr. James Paul Kastenmayer J.D., Ph.D.
Consultant
Mr. Jonathan D. Alspaugh M.B.A.
Pres, Chief Financial Officer & Principal Accounting Officer
Dr. Cameron Turtle DPHIL, Ph.D.
Chief Operating Officer
Mr. Jeffrey M. Goldberg
Pres, Chief Executive Officer & Director
Dr. Leslie S. Sloan Ph.D.
Chief Operating Officer
Ms. Cortney Caudill M.B.A.
Chief Product Officer
Dr. F. Andrew Dorr
Executive Officer
Ms. Tricia Sterling
Vice President of Patient Affairs
Mr. Michael C. Hanley M.B.A.
Chief Commercial Officer & Chief Bus. Officer
AGLE's closing price is 351.5% higher than its 52-week low of $2.66 where as its distance from 52-week high of $24.00 is -49.96%.
Number of AGLE employees currently stands at 69.
Official Website of AGLE is: https://www.aeglea.com
AGLE could be contacted at phone 512 942 2935 and can also be accessed through its website. AGLE operates from 805 Las Cimas Parkway, Austin, TX 78746, United States.
AGLE stock volume for the day was 43.24K shares. The average number of AGLE shares traded daily for last 3 months was 59.54K.
The market value of AGLE currently stands at $48.63M with its latest stock price at $12.01 and 4.05M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com